Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Lana E. Kandalaft, Denarda Dangaj, George Coukos
Nature reviews. Cancer (2022) Vol. 22, Iss. 11, pp. 640-656
Closed Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Heterogeneity and treatment landscape of ovarian carcinoma
Ana Veneziani, Eduardo González-Ochoa, Husam Alqaisi, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 820-842
Closed Access | Times Cited: 65
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma
David Barras, Eleonora Ghisoni, Johanna Chiffelle, et al.
Science Immunology (2024) Vol. 9, Iss. 92
Open Access | Times Cited: 35
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Lenka Kašíková, Jana Raková, Michal Hensler, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 32
Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in China: a multicentre, retrospective cohort study
Guangyao Cai, Fangjun Huang, Yue Gao, et al.
The Lancet Digital Health (2024) Vol. 6, Iss. 3, pp. e176-e186
Open Access | Times Cited: 18
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 14
Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer
Christine Y. Yeh, Karmen Aguirre, Olivia Laveroni, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1943-1958
Open Access | Times Cited: 13
Ovarian cancer-derived IL-4 promotes immunotherapy resistance
Gürkan Mollaoglu, Alexander Tepper, Chiara Falcomatà, et al.
Cell (2024)
Closed Access | Times Cited: 10
STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs)
Jiale Liu, Chenmian Liu, Yana Ma, et al.
Cancer Letters (2024) Vol. 588, pp. 216700-216700
Open Access | Times Cited: 9
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
Matthew S. Block, James H.A. Clubb, Johanna Mäenpää, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer
Shimin Yang, Jingxiao Du, Wei Wang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Transgelin 2 guards T cell lipid metabolism and antitumour function
Sung‐Min Hwang, Deepika Awasthi, Jeong Jieun, et al.
Nature (2024) Vol. 635, Iss. 8040, pp. 1010-1018
Closed Access | Times Cited: 7
Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment
Haiyao Hu, Chongen Sun, Jingyao Chen, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 3
Open Access | Times Cited: 6
Patient‐derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin
Yuqing Zhao, Chen Wang, Wei Deng, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 6
Identifying ITGB2 as a Potential Prognostic Biomarker in Ovarian Cancer
Chanyuan Li, Ting Deng, Junya Cao, et al.
Diagnostics (2023) Vol. 13, Iss. 6, pp. 1169-1169
Open Access | Times Cited: 15
Intratumoral CD103+CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
Siqi Ren, Tianjun Lan, Fan Wu, et al.
Cancer Communications (2023) Vol. 43, Iss. 10, pp. 1143-1163
Open Access | Times Cited: 15
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Won-Hee Yoon, Anna deFazio, Lawrence Kasherman
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 358-377
Open Access | Times Cited: 14
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Weisong Li, Kai Zhang, Wenjun Wang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 5
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer
Inga-Maria Launonen, Erdoğan Pekcan Erkan, Iga Niemiec, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
A Deep Learning–Based Assessment Pipeline for Intraepithelial and Stromal Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Carcinoma
Kohei Hamada, Ryusuke Murakami, Akihiko Ueda, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 7, pp. 1272-1284
Closed Access | Times Cited: 4
N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma
Alex Miranda, Swetansu Pattnaik, Phineas T. Hamilton, et al.
Science Advances (2024) Vol. 10, Iss. 20
Open Access | Times Cited: 4
The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature
Giulia Spagnol, Eleonora Ghisoni, Matteo Morotti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7070-7070
Open Access | Times Cited: 4
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
M.R. Mirza, Luka Tandarić, J R Henriksen, et al.
Gynecologic Oncology (2024) Vol. 188, pp. 103-110
Open Access | Times Cited: 4
Spatial tumor immune microenvironment phenotypes in ovarian cancer
Claudia Mateiou, Lavanya Lokhande, Lan Hoa Diep, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer
Tereza Láníčková, Michal Hensler, Lenka Kašíková, et al.
Clinical Cancer Research (2024), pp. OF1-OF17
Open Access | Times Cited: 4
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer
Inga-Maria Launonen, Iga Niemiec, María Mercedes Hincapié-Otero, et al.
Cancer Cell (2024) Vol. 42, Iss. 12, pp. 2045-2063.e10
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top